Seleniun/cancer claim
This article was originally published in The Tan Sheet
Executive Summary
Supplement maker Wellness Lifestyles d/b/a American Longevity seeks FDA approval of health claims stating selenium "may reduce the risk of certain cancers" and "may produce anticarcinogenic effects in the body." Petition filed July 10 notes claims "do not identify specific intake quantities for selenium," although studies have shown risk reduction with 50-200 mcg/day. Adult daily intake below 900 mcg "is unlikely to cause adverse reactions," Wellness adds. Petition cites six human clinical trials (three in China, and one each in U.S., India, Italy) on selenium supplementation and cancer incidence. Firm is represented by Emord & Associates (Washington, D.C.), which filed a health claim petition for phosphatidylserine and cognitive dysfunction/dementia in April (1"The Tan Sheet" May 6, 2002, p. 10)...
You may also be interested in...
Phosphatidylserine, Dementia, Cognitive Decline Health Claim Sought
No particular dose of phosphatidylserine works better at reducing the severity of cognitive dysfunction and the risk of dementia, according to a health claim petition filed with FDA April 19
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.